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Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) through binding to its recep-
tor fibroblast growth factor inducible 14 (Fn14) has been shown to regulate many cellular
responses including proliferation, differentiation, apoptosis, inflammation, and fibrosis,
under both physiological and pathological conditions. Emerging evidence suggests that
TWEAK is also a major muscle wasting cytokine. TWEAK activates nuclear factor-κB sig-
naling and proteolytic pathways such as ubiquitin–proteasome system, autophagy, and
caspases to induce muscle proteolysis in cultured myotubes. Fn14 is dormant or expressed
in minimal amounts in normal healthy muscle. However, specific atrophic conditions, such
as denervation, immobilization, and starvation stimulate the expression of Fn14 leading to
activation of TWEAK/Fn14 signaling and eventually skeletal muscle atrophy. TWEAK also
causes slow- to fast-type fiber transition in skeletal muscle. Furthermore, recent stud-
ies suggest that TWEAK diminishes mitochondrial content and represses skeletal muscle
oxidative phosphorylation capacity. TWEAK mediates these effects through affecting the
expression of a number of genes and microRNAs. In this review article, we have discussed
the recent advancements toward understanding the role and mechanisms of action of
TWEAK/Fn14 signaling in skeletal muscle with particular reference to different models of
atrophy and oxidative metabolism.
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INTRODUCTION
Skeletal muscle is the largest tissue of the human body, which
provides posture, ensures basic functions such as locomotion
and respiration, and plays a vital role in whole body metabo-
lism. Skeletal muscle is also one of the most highly plastic tissues
in the body. A number of extracellular and intracellular signals
have now been identified, which cause physiological adaptations
including enhanced substrate metabolism, mitochondrial biogen-
esis, angiogenesis, muscle growth, and regeneration (1, 2). For
example, exercise training causes improvement in muscle mass
and contractility, and metabolic function resulting in enhanced
force generation capacity and resistance to fatigability. Conversely,
inactivity and many chronic disease states result in loss of skele-
tal muscle mass and metabolic dysfunction (3, 4). Maintenance
of skeletal muscle mass and function are prerequisites for whole
body health throughout life.
Skeletal muscle mass is maintained through a delicate bal-
ance between protein synthesis and degradation. Resistance
exercise, hormones, and nutritional uptake increase rate of
protein synthesis resulting in increased muscle mass (5).
Insulin-like growth factor-1 (IGF-1)/phosphatidylinositol 3-
kinase (PI3K)/Akt/mTOR is one of the most important signaling
pathways, which increases protein synthesis leading to skeletal
muscle hypertrophy (6, 7). This pathway also inhibits muscle
protein degradation through distinct mechanisms (8, 9). By con-
trast, many catabolic stimuli increase the activity of various sig-
naling intermediates, such as extracellular-regulated kinase 1/2
(ERK1/2), c-Jun-N-terminal kinase (JNK), p38 mitogen-activated
protein kinase (MAPK), AMP-activated protein kinase (AMPK),
and TNF receptor-associated factors (TRAFs) and transcription
factors, such as nuclear factor-κB (NF-κB), activator protein 1
(AP1), p53, FoxO1, and FoxO3a resulting in the activation of
ubiquitin–proteasome system (UPS) and autophagy–lysosomal
system (ALS), the two major proteolytic mechanisms in skele-
tal muscle (1, 10, 11). Recent studies also suggest that activating
transcription factor 4 (ATF4), growth arrest and DNA damage-
inducible 45α (GADD45α), histone deacetylase 4 (HDAC4), and
myogenin mediate skeletal muscle atrophy under specific condi-
tions (12–14). Furthermore, changes in the mitochondrial content,
integrity, and function play a critical role in regulation of skeletal
muscle mass and function (15, 16). The biogenesis of new mito-
chondria and clearance of defunct mitochondria are essential to
meet cellular energy demand especially during endurance exercise
and to protect from many chronic diseases such as diabetes, heart
failure, obesity, and cancer (17, 18). Impairment in mitochondrial
function is also an important facet of aged skeletal muscle. How-
ever, it is not yet clear whether dysfunctional mitochondria are a
cause or consequence of aged skeletal muscle (19).
Classical proinflammatory cytokines, such as tumor necrosis
factor-α (TNFα), interleukin-1β (IL-1β), IL-6, and interferon-γ
have been suggested as important mediators of catabolic response
(protein loss and insulin resistance), contractile dysfunction, and
disruption of muscle regenerative ability in many chronic dis-
ease states (20–24). Although, neutralization of some of these
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cytokines attenuates muscle wasting, blocking their activity failed
to preserve skeletal muscle mass in some conditions where even
their abundance was significantly elevated suggesting that there
are additional mediators of muscle wasting (24). TNF-like weak
inducer of apoptosis (TWEAK), a member of the TNF super-
family, has recently been identified as an important mediator of
skeletal muscle wasting and metabolic dysfunction. While the lev-
els of several classical muscle wasting cytokines are increased in
various chronic disease states, there is no evidence about their
potential role in the loss of muscle mass in disuse conditions
(e.g., denervation, immobilization, and unloading). Our stud-
ies have shown that TWEAK/Fn14 system also mediates skeletal
muscle wasting in disuse conditions and even in response to
starvation. Moreover, increased levels of TWEAK inhibit skele-
tal muscle regenerative capacity through affecting self-renewal
of satellite cells and proliferation, fusion, and differentiation
of myoblasts into multinucleated myotubes both in vitro and
in vivo (25–29). The role of TWEAK/Fn14 signaling in regu-
lation of muscle progenitor cell biology has been discussed in
another article in this issue (30). We have focused our review
article to discuss the recent advancement toward understand-
ing the role and mechanisms of action of TWEAK in adult
skeletal muscle.
BRIEF OVERVIEW TWEAK/Fn14 DYAD
TWEAK is a member of TNF super family (TNFSF) cytokines,
which is initially synthesized as type II transmembrane protein
(249 amino acids) similar to TNF-α. However, membrane-bound
TWEAK is cleaved to its soluble form (156 amino acids) by
furin, a calcium-dependent serine endoprotease (31–33). Fn14,
a type I transmembrane protein, was first recognized by differ-
ential display analysis and later identified as the unique TWEAK
receptor (34–36). Fn14 is the smallest member (102 amino acids)
of TNF receptor super family (TNFRSF), which is expressed at
relatively low levels in normal healthy tissues except in progenitor
cells. However, the expression of Fn14 is drastically increased in
response to tissue injury and various pathological conditions (31,
33). Similar to other members of TNFRSF, the cytoplasmic domain
of Fn14 contains a TRAF binding site, which allows downstream
signaling upon stimulation by TWEAK (37). By contrast, Fn14
lacks a death domain and does not show any association with
death-inducing signaling complex (33). Furthermore, some stud-
ies suggest that Fn14 can also function by clustering themselves on
the cell membrane under low TWEAK condition. TWEAK/Fn14
system plays an important role in tissue homeostasis through
regulating cell survival, proliferation, migration, and angiogen-
esis (31, 33). Conversely, aberrant regulation of TWEAK/Fn14
signaling causes many pathological consequences including can-
cer, rheumatoid arthritis, systemic lupus erythematous, multiple
sclerosis, skeletal muscle wasting, and cardiac dysfunction and
failure (31).
Like other members of TNFSF, TWEAK mediates unique
and context-dependent pleiotropic effects. In contrast to TNF-
α, TWEAK attenuates the transition from innate to adap-
tive immunity by suppressing the production of interferon-γ
and IL-12 cytokines (38). Moreover, TWEAK activates multiple
intracellular pathways such as MAPK, PI3K/Akt, and canonical
and non-canonical NF-κB signaling in various cell types (39–
42). Binding of TWEAK leads to the formation of TRAF2/cIAP1
(cellular inhibitor of apoptosis protein 1) complex at Fn14 cyto-
plasmic domain that results in the activation of various signaling
proteins including TRAF6, transforming growth factor-β acti-
vated kinase1 (TAK1), I kappa β kinase (IKK), NF-κB-inducing
kinase (NIK), and MAPKs, which regulate expression of several
molecules involved in various cellular responses (Figure 1) (33,
39, 43–45). Moreover, the activation of TWEAK/Fn14 is cou-
pled with TNFα–TNFR1 signaling. For example, the activation of
TWEAK/Fn14 signaling sensitizes TNF-α signaling by exhausting
cytosolic TRAF2/cIAP1 complex (44).
TWEAK CAUSES ATROPHY IN CULTURED MYOTUBES
C2C12 as well as mouse primary myoblasts differentiate into
myotubes upon incubation in low serum conditions. These cul-
tured myotubes serve as an excellent model to study atrophy in
response to exogenously added molecules. We have previously
reported that treatment of cultured myotubes with even low con-
centrations of TWEAK protein causes severe atrophy (46, 47).
Multiple studies have shown that skeletal muscle atrophy is associ-
ated with rapid degradation of selective muscle proteins including
myosin heavy chain (MyHC) (48–50). Consistent with effects on
myotube size, addition of TWEAK led to significant reduction in
overall protein content and levels of MyHC in cultured myotubes
(46, 47). Moreover, at equimolar concentration, TWEAK was
found to be more potent in inducing MyHC degradation com-
pared with its structural homolog TNF-α suggesting that TWEAK
is a potent muscle wasting cytokine (47).
The UPS is one of the most important proteolytic systems that
cause selective degradation of muscle structural proteins (1, 11,
51). Two muscle-specific E3 ubiquitin ligases, muscle RING-finger
1 (MuRF1) and muscle atrophy F-box (MAFBx ; also known as
Atrogin-1) are the key enzymes of the UPS involved in degra-
dation of muscle proteins. Levels of both MuRF1 and MAFBx
are drastically increased in atrophying skeletal muscle, where dis-
ruption of these genes in mice preserves skeletal muscle mass
in many catabolic conditions, such as hind limb unloading, cast
immobilization, and denervation (1, 11, 52). ALS is another pro-
teolytic mechanism that contributes to degradation of muscle
proteins and cellular organelles in skeletal muscle in response
to various atrophic stimuli. In autophagy, cytosolic proteins and
organelles are sequestered by an isolation-membrane structure to
form autophagosome. The autophagosome then fuses with lyso-
some, where the autophagosome is degraded to amino acid or
peptide (53). Autophagy constitutively takes place at lower levels in
most cells under normal condition and is an essential component
of homeostasis machinery in different tissues including skele-
tal muscle (53, 54). However, excessive activation of autophagy
leads to muscle wasting in many conditions such as starvation and
denervation (8, 55).
Our studies have shown that TWEAK increases the gene expres-
sion of MuRF1 and MAFBx and stimulates the conjugation of
ubiquitin with MyHC in cultured myotubes (46, 47). Further-
more, TWEAK also induces the expression of several components
of ALS and activates caspases in cultured myotubes (46). Indeed,
inhibition of the activity of either UPS, autophagy, or caspases
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FIGURE 1 |TheTWEAK/Fn14 signaling cascade. TWEAK cytokine is
initially synthesized as membrane-anchored protein (mTWEAK). mTWEAK
is then cleaved by furin into soluble form of TWEAK (sTWEAK). Binding of
trimeric mTWEAK or sTWEAK to Fn14 receptor leads to the recruitment of
cIAPs and various TRAFs resulting in the activation of multiple downstream
signaling cascades. TWEAK stimulates canonical NF-κB pathway through
activation of TAK1 and IKKβ and phosphorylation and degradation of IκB
protein. TWEAK activates non-canonical NF-κB pathway through activation
of NIK and IKKα leading to proteolytic processing of p100 protein into p52.
TWEAK-mediated signaling also causes the activation of various MKKs,
which phosphorylate ERK1/2, ERK5, JNK, and p38MAPK resulting in the
activation of downstream transcription factors such as AP1 and SP1.
TWEAK, TNF-like weak inducer of apoptosis; Fn14, fibroblast growth factor
inducible 14; cIAP, cellular inhibitor of apoptosis; TRAF, TNF
receptor-associated factor; TAK1, transforming growth factor β-activated
kinase 1, TAB, TAK1 binding protein; IKK, IκB kinase β; IκB, inhibitor of
nuclear factor of kappa B; NIK, NF-κB-inducing kinase; MAPK,
mitogen-activated protein kinase; MKKs, mitogen-activated protein kinase
kinases; ERK, extracellular signal-regulating kinase; JNK, c-Jun N-terminal
kinase; AP1, activator protein 1; SP1, specificity protein 1.
significantly reduced TWEAK-induced degradation of MyHC and
myotube atrophy suggesting that TWEAK induces muscle pro-
teolysis through coordinated activation of multiple proteolytic
systems (46).
NF-κB is a major proinflammatory transcription factor, which
is strongly linked to skeletal muscle wasting not only in chronic
diseases but also in disuse conditions (10). Inhibition of NF-κB
has been found to rescue skeletal muscle atrophy in response to
cytokines, tumor growth, denervation, and unloading (10, 56).
By contrast, forced activation of NF-κB is sufficient to cause
severe muscle wasting in mice (56). NF-κB induces muscle atro-
phy through augmenting the expression of MuRF1 and several
other components of UPS (10). It has been recently reported that
MuRF1 causes breakdown of MyHC and other components of
the thick filament of the sarcomere during atrophy (57, 58). Our
studies have shown that TWEAK causes sustained activation of
NF-κB. Furthermore, inhibition of NF-κB through pharmacolog-
ical or molecular approaches prevents the degradation of MyHC
and atrophy in cultured myotubes (46, 47, 59, 60). Although,
TWEAK did not inhibit protein synthesis, it inhibited the activa-
tion of PI3K/Akt/mTOR signaling pathway in cultured myotubes
(47). Similarly, TWEAK has also been found to inhibit the insulin-
induced Akt phosphorylation in hepatocytes (61). Since Akt sig-
naling inhibits the activity of FoxO family of transcription factors,
which are required for the expression of MuRF1 and MAFBx (1),
it is likely that the inhibition of Akt signaling is another mecha-
nism by which TWEAK augments the gene expression of MuRF1
and MAFBx in cultured myotubes. Collectively, these observations
suggest that TWEAK causes atrophy in cultured myotubes through
the activation of NF-κB and various proteolytic systems such as
UPS, ALS, and caspases (Figure 2).
The effect of TWEAK on global gene expression and microR-
NAs (miRs) in cultured myotubes has also been investigated.
Pathway analysis of microarray gene expression data suggested that
TWEAK affects the activation of several toxic pathways including
those involved in initiation and manifestation of fibrosis, oxidative
stress, and mitochondrial dysfunction in skeletal muscle (62). For
example, TWEAK reduces the expression of structural molecules
www.frontiersin.org January 2014 | Volume 5 | Article 18 | 3
Sato et al. TWEAK signaling in skeletal muscle
FIGURE 2 | Mechanisms of action ofTWEAK/Fn14 system in skeletal
muscle atrophy. Specific catabolic conditions such as denervation,
starvation, immobilization, unloading, burn injury, and aging augments the
expression of Fn14 resulting in stimulation of TWEAK/Fn14 signaling in
skeletal muscle. TWEAK-Fn14 signaling represses the levels of PGC-1α and
myomiRs and increases the activation of NF-κB, UPS, ALS, caspases, and
MMP-9, which eventually cause loss of skeletal muscle mass. Fn14, fibroblast
growth factor inducible 14; TWEAK, TNF-like weak inducer of apoptosis;
PGC-1α, peroxisome proliferator-activated receptor-gamma coactivator 1α;
MMP-9, matrix metalloproteinase-9; NF-κB, nuclear factor-kappa B; UPS,
ubiquitin–proteasome system; ALS, autophagy–lysosome system; myomiRs,
muscle microRNAs.
(e.g. MyHC, TCap, and ankyrin repeat domain 2), metabolic
enzymes (e.g., phosphoglycerate mutase 2), and signaling pro-
teins (e.g., Notch1 and TRAF6) in C2C12 myotubes. By contrast,
TWEAK induces the expression of multiple components of NF-κB
signaling pathways and expression of matrix metalloproteinase-9
(MMP-9) in myotubes (62). Recently, a few muscle-specific miRs
such as miR-1, miR-133a, miR-133b, and miR-206 (also called
myomiRs) have been identified, which are essential for muscle
progenitor cell proliferation, differentiation, and maintenance.
Expression of miR-1 and miR-133a in embryonic stem cells and
other non-muscle cell types showed that they promote the differ-
entiation into the skeletal muscle lineage. Unlike other myomiRs,
which are also expressed in cardiac tissues, miR-133b and miR-206
are predominantly expressed in skeletal muscle (63). Interestingly,
microarray analysis of miRs has shown that TWEAK reduces the
expression levels of miR-1, miR-133a, miR-133b, and miR-206
in cultured myotubes (62). Recent studies have demonstrated that
myogenic transcription factors, such as myocyte enhancer factor 2c
(MEF2c) and MyoD control the expression of myomiRs in skele-
tal and cardiac muscles (63). Interestingly, TWEAK diminishes the
levels of both MEF2c and MyoD (25, 62) suggesting that reduced
expression of myomiRs could be a result of diminished abundance
of MEF2c and MyoD in TWEAK-treated myotubes. TWEAK also
regulates the expression of a number of other miRs, which are
involved in distinct biological responses. Using differentially reg-
ulated miR data set, we generated a network of pathways from
differentially regulated genes in cDNA microarray data set. This
analysis showed that miRs network overlaps with mRNA networks
suggesting that miRs may play important roles in the regulation
of gene expression and skeletal muscle structure and function in
response to TWEAK (62).
TWEAK CAUSES SKELETAL MUSCLE ATROPHY IN VIVO
In vivo effects of TWEAK on skeletal muscle were first investi-
gated by systemic and chronic administration of soluble TWEAK
proteins in wild-type mice. Chronic administration of TWEAK in
mice led to a significant reduction in whole body weight, individ-
ual muscle mass, and fiber-cross-sectional area (47). Furthermore,
transgenic (Tg) overexpression of full-length TWEAK using mus-
cle creatine kinase (MCK) promoter resulted in smaller muscle size
and neonatal lethality in mice (47). TWEAK-Tg mice, which sur-
vived due to relatively low expression of TWEAK (four to sixfolds
higher than littermate controls) showed muscle atrophy and inter-
stitial fibrosis at around 4–6 months of age (43). Consistent with
in vitro studies, transcript levels of MuRF1 and ubiquitination of
MyHC were significantly elevated in skeletal muscle of TWEAK-
Tg mice compared with their littermate controls. By contrast, there
was no significant difference in mRNA levels of MAFBx in skeletal
muscle of wild-type and TWEAK-Tg mice indicating that TWEAK
causes muscle atrophy in vivo through augmenting the expression
of MuRF1 (43, 62). Furthermore, the gene expression of several
components of NF-κB signaling pathway and DNA-binding activ-
ity of NF-κB were significantly increased in skeletal muscle of
TWEAK-Tg mice (43). These findings suggest that the activa-
tion of NF-κB pathway is one of the important mechanisms for
TWEAK-induced muscle proteolysis (Figure 2).
Accumulating evidence suggests that peroxisome proliferator-
activated receptor γ (PPAR-γ) coactivator 1α (PGC-1α) plays a key
role in preserving skeletal muscle mass and mitochondrial content
in atrophic conditions (64). Levels of PGC-1α are repressed in
multiple atrophy conditions whereas muscle-specific overexpres-
sion of PGC-1α rescues the loss of skeletal muscle mass in catabolic
states (65, 66). Our recent studies demonstrate that TWEAK
represses the expression of PGC-1α in cultured myotubes (67).
Overexpression of PGC-1α inhibits TWEAK-induced atrophy,
NF-κB activation, and expression of MAFBx and MuRF1 in cul-
tured myotubes. Moreover, progressive muscle atrophy observed
in TWEAK-Tg mice is significantly attenuated in TWEAK-PGC-
1α double Tg mice suggesting that PGC-1α plays an important
role in TWEAK-induced muscle atrophy (67).
Another potential mechanism by which TWEAK causes mus-
cle atrophy is through deregulation of matrix metalloproteinases
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(MMPs). Protein levels as well as enzymatic activity of MMP-9 are
significantly elevated in skeletal muscle of TWEAK-Tg mice (59,
62). Since,muscle atrophy in response to chronic administration of
TWEAK is rescued to some extent in Mmp9-knockout (KO) mice,
it is likely that MMP-9 is involved in TWEAK-induced skeletal
muscle wasting in vivo. Elevated levels of MMP-9 can potentially
induce muscle atrophy through breakdown of extracellular matrix
and proteolytic activation of other catabolic cytokines (59). In
agreement with microarray data in TWEAK-treated myotubes, we
have found that the levels of many structural molecules such as
MyHC, TCap, and ankyrin repeat domain 2 and myomiRs were
reduced in skeletal muscle of TWEAK-Tg mice suggesting that
TWEAK also causes atrophy through repression of specific muscle
proteins (62).
TWEAK/Fn14 SYSTEMMEDIATES MUSCLE ATROPHY IN
CATABOLIC CONDITIONS
Muscle atrophy can be observed in various physiological and
pathophysiological conditions such as bed-rest, space flight, aging,
cancer, severe burn injury, starvation, high dose glucocorticoid
therapy, and neurotmesis (2). Our group and others have recently
investigated whether the gene expression of TWEAK or Fn14 is
affected in skeletal muscle in different atrophy conditions. Inter-
estingly, the gene expression of Fn14 is dramatically induced
in skeletal muscle in disuse conditions such as denervation and
immobilization (43) and in response to starvation (48). Wu et al.
studied the global gene expression in skeletal muscle of mice in
response to hind limb suspension, a model to elicit unloading-
induced skeletal muscle atrophy. Microarray and quantitative
real-time PCR assays showed that the gene expression of Fn14 is
significantly increased in skeletal muscle of mice (68). Moreover,
a recent study has also demonstrated that the levels of TWEAK
and Fn14 are increased in human skeletal muscle in response to
severe burn injury (69). By contrast, mRNA levels of TWEAK and
Fn14 remained unaffected in skeletal muscle of mice in response
to high doses of glucocorticoids (43) and in skeletal muscle of
patients with chronic obstructive pulmonary disease (70) indicat-
ing that TWEAK/Fn14 system may not be the mediator of muscle
atrophy in all conditions.
The physiological role of TWEAK/Fn14 system in muscle atro-
phy has been investigated through a series of experiments using
denervated hind limb muscle as a model of neurotmesis (43).
Levels of Fn14 protein are dramatically increased upon denerva-
tion regardless of muscle fiber type (43). Denervation-induced
loss of skeletal muscle mass and fiber cross-sectional-area were
significantly exaggerated in TWEAK-Tg mice but ameliorated in
TWEAK-KO mice compared with wild-type mice. Denervated
soleus muscle of TWEAK-KO mice showed improved absolute
force compared with corresponding wild-type mice. Skeletal mus-
cle of TWEAK-Tg mice also showed increased gene expression
of collagen I and collagen III and interstitial fibrosis upon den-
ervation indicating that TWEAK can directly induce fibrosis in
skeletal muscle tissues. Similar to cell culture studies, TWEAK
stimulated the DNA-binding activity of NF-κB and increased
the gene expression of MuRF1 in denervated skeletal muscle
(43). Furthermore, starvation-induced loss of skeletal muscle
mass was reduced in TWEAK-KO mice compared with wild-type
mice (43). Collectively, these studies provide strong evidence that
TWEAK/Fn14 system mediates muscle atrophy in catabolic condi-
tions (Figure 2). It is noteworthy that denervation and starvation
did not affect the expression TWEAK in skeletal muscle of mice.
Similar to studies in rodents, a recent study reported that chronic
hemiplegia-induced muscle atrophy was not accompanied with
changes in expression of TWEAK in humans (71).
While TWEAK affects the activation of a number of signaling
pathways and proteolytic systems in cultured myotubes, only a
few of them appear to be regulated by TWEAK in skeletal muscle
of mice in atrophic conditions. For example, TWEAK inhibits
the activity of PI3K/Akt pathway in cultured myotubes; how-
ever, there was no difference in level of phosphorylation of Akt
in denervated muscle of wild-type, TWEAK-Tg and TWEAK-
KO mice. Furthermore, while denervation increased expression
of several autophagy-related genes (such as LC3B, Beclin1, Atg5,
Atg12, and Gabarapl1), their expression levels were compara-
ble in denervated skeletal muscle of wild-type, TWEAK-Tg and
TWEAK-KO mice (43). These results suggest that denervated
skeletal muscle is enriched with certain growth factors, which
neutralize some of the actions of TWEAK. However, we can-
not rule out that TWEAK/Fn14 signaling also affects the acti-
vation of PI3K/Akt and ALS in other conditions of muscle
atrophy.
REGULATION OF Fn14 EXPRESSION IN SKELETAL MUSCLE
While, it is increasingly clear that the expression of Fn14 is a
rate-limiting step, molecular mechanisms leading to its increased
expression in skeletal muscle in atrophic conditions remain poorly
understood. Both human and mouse Fn14 promoters lack a typical
TATA box, which is generally required for the expression of mam-
malian genes. However, the promoter region of Fn14 contains
consensus sequence for several transcription factors (72). Recent
studies in our laboratory have shown that mouse and human
Fn14 promoters contain a cytosine–guanine dinucleotide (CpG)
island close to transcription start site. Fn14 promoter also contains
consensus DNA sequence for AP1 and specificity protein 1 (SP1)
transcription factors. Our studies suggest that denervation causes
hypomethylation at specific CpG sites in mouse Fn14 promoter
in skeletal muscle. Interestingly, while all three DNA methyltrans-
ferases (Dnmts) interact with Fn14 promoter in naïve muscle, the
levels of DNA methyltransferase 3a (Dnmt3a) are repressed in
denervated skeletal muscle of mice. The role of Dnmt3a in Fn14
expression has been supported by our findings that overexpres-
sion of Dnmt3a inhibits the expression of Fn14 and attenuates
denervation-induced muscle atrophy. We have also found that
denervation increases the activation of MAPK, AP1, and SP1 and
they are involved in the expression of Fn14 in denervated skeletal
muscle.
TWEAK PROMOTES SLOW-TO-FAST FIBER TYPE
TRANSITION IN SKELETAL MUSCLE
Rodent skeletal muscle contains four fiber types based on the pri-
mary expression of MyHC: I, IIA, IIX, and IIB (73, 74). Type
I fibers are slow to twitch by stimuli, display a two to three-
fold higher mitochondrial content, and rely largely on oxidative
metabolism to produce ATP. In contrast, type II fibers are fast
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in responding to stimuli and rely on glycolytic metabolism as a
major energy substrate (75). Type IIB fibers have relatively few
mitochondria and store large amounts of glycogen; therefore they
are glycolytic in metabolism. Types IIA and IIX fibers have phys-
iologically intermediate properties of slow and fast twitch fibers,
which are also rich in mitochondria and possess a relatively high
capacity to generate ATP by oxidative metabolism (76, 77). More-
over, it is now increasingly evident that different fiber types display
different sensitivity to atrophy stimuli. Oxidative fibers are some-
what resilient to atrophy upon denervation (78) whereas glycolytic
fibers undergo more rapid atrophy in response to starvation or
sepsis (79, 80).
TWEAK/Fn14 axis appears to be an important regulator of
fiber type composition in skeletal muscle. Tg overexpression of
TWEAK in mice causes a significant reduction in proportion of
type I fibers with a concomitant increase in type II fibers in both
soleus and extensor digitorum longus muscle (43). Moreover, hind
limb muscle of the founder TWEAK-Tg mice, which could not sur-
vive beyond neonatal age, appeared pale compared with wild-type
littermates indicating lower myoglobin abundance and fast muscle
phenotype in TWEAK overexpressing muscle (47). By contrast,
proportion of types I and IIA muscle fibers and skeletal muscle
mitochondrial content was found to be increased in skeletal muscle
of TWEAK-KO mice (43, 81). These results suggest that TWEAK
favors fast-type fiber phenotype even under normal conditions.
Recent studies have shown that PGC-1α plays an important
role in regulating skeletal muscle fiber composition, mitochondr-
ial content, and oxidative metabolism in both physiological and
pathophysiological conditions (64, 82, 83). PGC-1α is expressed
preferentially in skeletal muscle enriched in type I fibers. Pos-
itive role of PGC-1α in inducing type I fibers is supported by
the findings that Tg overexpression of PGC-1α in skeletal muscle
increases the proportion of types I and IIA fibers (84). Conversely,
muscle-specific PGC-1α KO mice exhibited a shift from oxida-
tive types I and IIA toward types IIX and IIB muscle fibers (85)
while global PGC-1α KO mice did not show a marked skeletal
muscle phenotype (85, 86). PGC-1α drives the transcription of
type I muscle fibers through co-activation of myocyte enhancer
factor 2 (MEF2) family members such as MEF2c and MEF2d
(84). MEF2 and PGC-1α also regulate the expression of PGC-1α
in an auto-regulatory loop (87). Interestingly, our recent studies
have shown that TWEAK suppresses the expression of MEF2c in
C2C12 myotubes (62). Therefore, it is likely that TWEAK increases
the number of type II fibers through reducing MEF2/PGC-1α
signaling (Figure 3). Supporting this notion, our recent study
has demonstrated that transcript levels of PGC-1α and several
molecules involved in mitochondrial oxidative metabolism are
significantly increased in skeletal muscle of 5-month-old TWEAK-
KO mice. Furthermore, treatment of cultured primary myotubes
with TWEAK drastically reduced levels of PGC-1α and other
mitochondria-related genes (81). Likewise, an inverse relation-
ship between TWEAK and PGC-1α has been observed in dener-
vated skeletal muscle of mice (67). Since type II muscle fibers are
more susceptible to atrophy compared to type I muscle fibers in
many chronic diseases, it will be interesting to investigate whether
slow- to fast-type fiber transition is essential for TWEAK-induced
muscle atrophy.
FIGURE 3 | Putative mechanisms by whichTWEAK–Fn14 system
inhibits skeletal muscle oxidative phosphorylation capacity.
TWEAK/Fn14 system activates canonical NF-κB signaling pathway, which
represses PGC-1α levels in skeletal muscle. This leads to reduced
expression of several mitochondrial genes and proportion of type I fibers.
TWEAK also decreases the expression of miR-206, a positive regulator of
type I fibers. TWEAK, TNF-like weak inducer of apoptosis; Fn14, fibroblast
growth factor inducible 14; NF-κB, nuclear factor-kappa B; PGC-1α,
peroxisome proliferator-activated receptor-gamma coactivator 1α; miR-206,
microRNA-206.
TWEAK INHIBITS SKELETAL MUSCLE OXIDATIVE
METABOLISM
Skeletal muscle, due to its large mass, is the principal organ for
glucose disposal in the body and therefore even a small reduc-
tion in skeletal muscle glucose uptake capacity or its ability to
metabolize glucose is sufficient to cause metabolic abnormalities
and obesity. The decline in skeletal muscle oxidative phospho-
rylation capacity during aging has been recognized as a major
cause for increased fatigability, lowered quality of life, and mor-
bidity (19). The loss of oxidative capacity with elevated levels
of proinflammatory cytokines is also implicated in development
of metabolic syndrome in many chronic disease states, while the
maintenance with exercise has been found to be beneficial to some
extent (88, 89).
We have recently studied the role of TWEAK in exercise tol-
erance and skeletal muscle oxidative phosphorylation capacity.
TWEAK-KO mice run longer and with higher speed in a tread-
mill exercise tolerance test (81). Furthermore, TWEAK-KO mice
show augmented levels of subsarcolemmal and intermyofibrillar
mitochondria, increased succinate dehydrogenase (SDH)-positive
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myofibers, and elevated gene expression of metabolic proteins such
as PGC-1α, PPARδ, and mCPT-1. Moreover, oxidative phospho-
rylation is also increased in exercised TWEAK-KO mice compared
with wild-type mice. Consistent with studies in TWEAK-KO
mice, treatment of cultured myotubes with TWEAK decreased
mitochondrial biogenetic capacity and maximal respiratory activ-
ity. TWEAK also reduced the expression of PGC-1α and several
mitochondrial genes in cultured myotubes (81). Recent studies
also suggest that TWEAK represses PGC-1α in cultured car-
diomyocytes and myotubes through the activation of canonical
NF-κB signaling pathway (67, 90). Collectively, these studies sug-
gest that the repression of PGC-1α is an important mechanism
by which TWEAK reduces mitochondrial content and oxidative
phosphorylation capacity in skeletal muscle and in other cell
types.
There is also a possibility that TWEAK inhibits skeletal mus-
cle oxidative phosphorylation capacity through affecting levels of
various miRs. The expression of miRs is sensitive to cytokine lev-
els and alternation of miRs in response to inappropriate cytokine
simulation may result in disrupting metabolic homeostasis (91). A
subset of muscle-specific miRs has been shown to play an impor-
tant role in skeletal muscle development and metabolic adaptation
(92). Abundance of miR-206 is significantly higher in slow-type
skeletal muscle compared with fast-type muscle (93). Levels of
miR-206 are diminished during slow-to-fast fiber type transition
in response to unloading (94). Furthermore, levels of miR-206 in
vastus lateralis have been found to be significantly decreased in
patients with type II diabetes compared with healthy individu-
als (95). Our low-density miRNA array analysis has shown that
TWEAK inhibits the expression of miR-206 in C2C12 myotubes
(62). These findings suggest that TWEAK may also inhibit skele-
tal muscle oxidative metabolism through down-regulation of
miR-206 levels (Figure 3).
CONCLUDING REMARKS
The studies summarized above indicate that TWEAK/Fn14 system
plays an essential role in skeletal muscle remodeling and metab-
olism. Most of these observations suggest that TWEAK/Fn14
signaling causes loss of skeletal muscle mass and decreases skele-
tal muscle oxidative metabolism implying that the inhibition of
this cytokine-receptor axis can be used as a therapy to main-
tain skeletal muscle mass and metabolic function. We believe
that TWEAK/Fn14 system is among the most attractive drug
targets to combat muscle wasting. TWEAK being an extracellu-
lar protein per se, TWEAK-dependent signaling can be blocked
using a TWEAK neutralizing antibody or soluble Fn14-Fc decoy
protein, which prevents TWEAK binding to Fn14 cell surface
receptors. Indeed, these two reagents have been found to be
effective in improving pathologic condition in mouse mod-
els of some other diseases where TWEAK/Fn14 signaling is
elevated. Alternatively, small-molecule antagonists that prevent
Fn14 trimerization or interaction of TWEAK with Fn14 can
also be used to block catabolic actions of TWEAK in skeletal
muscle.
Whereas the role of TWEAK/Fn14 signaling in skeletal mus-
cle has become increasingly clear, there are still some outstanding
questions that need to be addressed. For example, it is important to
identify other conditions where TWEAK/Fn14 axis is a mediator
of muscle wasting. Furthermore, it is important to investigate the
mechanism by which TWEAK causes metabolic abnormalities and
whether the inhibition of TWEAK/Fn14 signaling can prevent type
II diabetes and obesity in response to high fat diet. It will also
be interesting to examine whether TWEAK affects mitochondr-
ial content through regulating mitochondria biogenesis, fusion,
fission, or mitophagy. The role of various miRs in regulation
of TWEAK-induced muscle atrophy and metabolic dysfunction
also needs more investigation. Nevertheless, recent studies have
provided strong evidence that TWEAK/Fn14 system is a major
regulator of skeletal muscle mass and function.
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